Alnylam Pharmaceuticals, Inc. (ALNY) to Post FY2018 Earnings of ($5.56) Per Share, Jefferies Group Forecasts
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Jefferies Group boosted their FY2018 earnings estimates for shares of Alnylam Pharmaceuticals in a report issued on Wednesday. Jefferies Group analyst M. Raycroft now expects that the biopharmaceutical company will post earnings per share of ($5.56) for the year, up from their previous estimate of ($5.70). Jefferies Group has a “Buy” rating and a $130.00 price objective on the stock. Jefferies Group also issued estimates for Alnylam Pharmaceuticals’ FY2020 earnings at ($3.02) EPS and FY2021 earnings at $0.30 EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.05) earnings per share.
WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) to Post FY2018 Earnings of ($5.56) Per Share, Jefferies Group Forecasts” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-to-post-fy2018-earnings-of-5-56-per-share-jefferies-group-forecasts/1600045.html.
Several other equities research analysts also recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and set a $124.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, September 25th. Stifel Nicolaus reaffirmed a “hold” rating and set a $83.00 price target (up from $56.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 20th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $116.00 price target (up from $110.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 20th. Cowen and Company reaffirmed an “outperform” rating and set a $117.00 price target (up from $93.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 20th. Finally, Needham & Company LLC increased their price target on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, September 20th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $94.33.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 117.49 on Friday. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $119.02. The stock’s market capitalization is $10.78 billion. The company’s 50-day moving average price is $81.14 and its 200 day moving average price is $69.12.
Institutional investors have recently modified their holdings of the stock. Pacer Advisors Inc. lifted its stake in Alnylam Pharmaceuticals by 22.0% in the 2nd quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock valued at $926,000 after buying an additional 2,093 shares in the last quarter. Hemenway Trust Co LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $235,000. BlackRock Inc. lifted its stake in Alnylam Pharmaceuticals by 34,755.2% in the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares in the last quarter. Federated Investors Inc. PA lifted its stake in Alnylam Pharmaceuticals by 522.9% in the 2nd quarter. Federated Investors Inc. PA now owns 62,293 shares of the biopharmaceutical company’s stock valued at $4,968,000 after buying an additional 52,293 shares in the last quarter. Finally, Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $320,000. 94.25% of the stock is currently owned by hedge funds and other institutional investors.
In related news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.30% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.